BioLine RX’s Execs Keep Stakes Quiet, Relying on New Mega‑Option Grants to Signal Confidence Amid Stock Slide
BioLine RX insiders grant 2 M+ options to keep cash, signal long‑term confidence amid a volatile share price.
5 minutes to read
BioLine RX Ltd
CEO Serlin Keeps Shares Flat as BioLine RX Faces GLIX1 Trial Uncertainty — Signal of Long‑Term Confidence Amid Market Volatility
CEO Serlin Philip A keeps BioLine RX shares steady amid volatility, reflecting confidence in GLIX1 trials and a structured option plan that could boost share value.
3 minutes to read